# of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

> **NCT05601336** · PHASE3 · UNKNOWN · sponsor: **Beni-Suef University** · enrollment: 200 (estimated)

## Conditions studied

- PCO

## Interventions

- **DRUG:** Dapagliflozin 5 MG
- **DRUG:** Metformin Hydrochloride 1000 MG
- **DRUG:** Dapagliflozin/Metformin

## Key facts

- **NCT ID:** NCT05601336
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-15
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601336, "of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT05601336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*